These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 21790210)

  • 41. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
    Kowarik MC; Pellkofer HL; Cepok S; Korn T; Kümpfel T; Buck D; Hohlfeld R; Berthele A; Hemmer B
    Neurology; 2011 Apr; 76(14):1214-21. PubMed ID: 21464424
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.
    Derfuss T; Ontaneda D; Nicholas J; Meng X; Hawker K
    Mult Scler Relat Disord; 2016 Jul; 8():124-30. PubMed ID: 27456887
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].
    Aktas O; Ingwersen J; Kieseier B; Küry P; Hohlfeld R; Hartung HP
    Nervenarzt; 2011 Feb; 82(2):215-25. PubMed ID: 20842337
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
    Brinkmann V
    Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral fingolimod (FTY720) for relapsing multiple sclerosis.
    Kappos L; Antel J; Comi G; Montalban X; O'Connor P; Polman CH; Haas T; Korn AA; Karlsson G; Radue EW;
    N Engl J Med; 2006 Sep; 355(11):1124-40. PubMed ID: 16971719
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emerging therapies in relapsing-remitting multiple sclerosis.
    Marriott JJ; O'Connor PW
    Rev Recent Clin Trials; 2010 Sep; 5(3):179-88. PubMed ID: 20500147
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of reduced fingolimod dosage treatment.
    Yamout BI; Zeineddine MM; Sawaya RA; Khoury SJ
    J Neuroimmunol; 2015 Aug; 285():13-5. PubMed ID: 26198913
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
    Yeh EA; Weinstock-Guttman B
    Adv Ther; 2011 Apr; 28(4):270-8. PubMed ID: 21394595
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
    Hla T; Brinkmann V
    Neurology; 2011 Feb; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
    Chiba K; Adachi K
    Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
    Széplaki G; Merkely B
    Ideggyogy Sz; 2012 Nov; 65(11-12):369-76. PubMed ID: 23289171
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical pharmacokinetics of fingolimod.
    David OJ; Kovarik JM; Schmouder RL
    Clin Pharmacokinet; 2012 Jan; 51(1):15-28. PubMed ID: 22149256
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fingolimod modulates microglial activation to augment markers of remyelination.
    Jackson SJ; Giovannoni G; Baker D
    J Neuroinflammation; 2011 Jul; 8():76. PubMed ID: 21729281
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.
    Voon V; Saiva L; O'Kelly S; Keane D
    Eur J Clin Pharmacol; 2014 Mar; 70(3):373-5. PubMed ID: 24309839
    [No Abstract]   [Full Text] [Related]  

  • 55. Evaluation of efficacy, safety and tolerability of fingolimod in patients with the relapsing form of multiple sclerosis - 12-month observation. A preliminary report.
    Maciejek Z; Wójcik-Drączkowska H; Wawrzyniak S; Niezgodzińska-Maciejek A
    Neurol Neurochir Pol; 2013; 47(2):145-51. PubMed ID: 23650003
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions.
    Muris AH; Rolf L; Damoiseaux J; Koeman E; Hupperts R
    BMC Neurol; 2014 Aug; 14():164. PubMed ID: 25138918
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
    Warnke C; Wiendl H; Hartung HP; Stüve O; Kieseier BC
    Drug Des Devel Ther; 2010 Jul; 4():117-26. PubMed ID: 20689698
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.
    Cascione M; Wynn D; Barbato LM; Pestreich L; Schofield L; McCague K
    J Med Econ; 2013 Jul; 16(7):859-65. PubMed ID: 23647445
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
    Hiestand PC; Rausch M; Meier DP; Foster CA
    Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
    Chiba K
    Yakugaku Zasshi; 2009 Jun; 129(6):655-65. PubMed ID: 19483408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.